<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40310">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064023</url>
  </required_header>
  <id_info>
    <org_study_id>H12-02375</org_study_id>
    <nct_id>NCT02064023</nct_id>
  </id_info>
  <brief_title>Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy</brief_title>
  <official_title>Comparison of Continuous Subcutaneous Insulin Infusion (CSII) With Multiple Daily Injections (MDI) for the Treatment of Pregestational Diabetes During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating whether insulin treatment with the insulin pump or with multiple
      daily injections (MDI) gives better outcomes for mother and baby in pregnant women with
      pregestational diabetes. Participants will be randomized to use either the insulin pump or
      MDI.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite obstetrical/perinatal endpoint consisting of specific elements (see description)</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Composite obstetrical/perinatal endpoint consisting of one or more of pre-eclampsia, primary caesarian section, pre-term delivery, spontaneous abortion, termination for congenital anomaly or chromosomal abnormality, perinatal mortality, large-for-gestational age, shoulder dystocia, birth injury, major congenital anomaly, neonatal hypoglycemia, jaundice requiring phototherapy, or admission to neonatal intensive care nursery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean maternal HbA1c during pregnancy</measure>
    <time_frame>up to 42 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HbA1c will be measured at least every three months to provide information about overall glycemic control</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of episodes of severe hypoglycemia</measure>
    <time_frame>up to 42 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Severe hypoglycemia is defined as capillary glucose &lt; 3.3 mmol/L requiring the assistance of another person for treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>insulin pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will use an insulin pump for the duration of the pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Daily Insulin injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will continue their usual insulin treatment with multiple daily injections of sc insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Animas</intervention_name>
    <description>subjects in the experimental arm will administer insulin using a pump</description>
    <arm_group_label>insulin pump</arm_group_label>
    <other_name>insulin pump</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>multiple daily insulin injection</intervention_name>
    <description>Subjects will continue with usual insulin injections</description>
    <arm_group_label>Multiple Daily Insulin injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects are attending the Diabetes Pregnancy Clinic at participating hospitals

          -  have had type 1 or type 2 diabetes for at least one year

          -  are in the first trimester or are actively attempting pregnancy

          -  have a singleton pregnancy

          -  are receiving intensive insulin therapy

          -  are judged by clinic staff to be capable of using an insulin pump

          -  are age 19 or older

          -  are willing to adhere to the study protocol including monitoring blood glucose levels

          -  are willing to take folic acid before pregnancy and during the first trimester

          -  are willing to discontinue any medication contraindicated in pregnancy prior to
             conception

          -  weigh less than 100 kg (220 lb) prior to becoming pregnant

          -  use less than 100 units of insulin per day

        Exclusion Criteria:

          -  current or previous use of an insulin pump

          -  use of fertility treatments

          -  have a multiple pregnancy

          -  have had children born with major birth defects

          -  have experienced stillbirth or multiple early pregnancy losses

          -  have significant diabetes complications or a serious medical issue
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David M Thompson, MD</last_name>
    <phone>604-875-5996</phone>
    <email>david.thompson@vch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon E Thompson, RN</last_name>
    <phone>604-875-2339</phone>
    <email>sharon.thompson@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jim Pattison Outpatient Care and Surgery Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3T 0G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reena Khurana, MD</last_name>
      <email>kreena@mail.ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Reena Khurana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>B.C. Women's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David M Thompson, MD</last_name>
      <phone>604-875-5996</phone>
      <email>david.thompson@vch.ca</email>
    </contact>
    <investigator>
      <last_name>David M Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>February 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin pump</keyword>
  <keyword>CSII</keyword>
  <keyword>multiple daily injections</keyword>
  <keyword>MDI</keyword>
  <keyword>type 1 diabetes</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>pregnancy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
